6. A Four-Pillared Therapeutic Strategy in Diabetic Kidney Disease: Integrating RAS Blockade, SGLT2 Inhibitors, GLP-1 RAs, and ns-MRAs for Optimal Cardiorenal Protection. This evidence concerns the gene SLC5A2 and diabetic kidney disease.